Scilex Holding
SCLX
About: Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.
Employees: 31
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
8.43% more ownership
Funds ownership: 0.52% [Q1] → 8.96% (+8.43%) [Q2]
15% less funds holding
Funds holding: 78 [Q1] → 66 (-12) [Q2]
24% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 45
29% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 17
67% less capital invested
Capital invested by funds: $11M [Q1] → $3.65M (-$7.4M) [Q2]
Financial journalist opinion